Indoco Remedies receives EIR from USFDA for Goa Plant-I
The PAI was conducted for two drug product applications (ANDAs) filed from this facility
The PAI was conducted for two drug product applications (ANDAs) filed from this facility
This product will be manufactured by Indoco Remedies at their manufacturing facility located at Goa
The company has reported total income of Rs. 486.16 crores during the period ended September 30, 2023
USFDA issued issued Form 483 with nine observations, which will be addressed within stipulated time.
According to IQVIA sales data for the period ending January 2022, Vimpat tablets market achieved annual sales of approx. US $ 1.7 billion
The production started from its greenfield manufacturing facility at Aurangabad in Maharashtra
The EU certification will support supplies of drug products registered in Europe, from this manufacturing site
Indoco expects this change in compliance status to pave the way for approvals of ANDAs submitted from this site.
The Innopack confex is a perfect platform for exhibitors to demonstrate their latest developments in the fields of pharmaceutical packaging, labelling, drug delivery device design and engineering.
Subscribe To Our Newsletter & Stay Updated